“`html
Fluorouracil and Capecitabine: Updated Warnings for DPD Deficiency
Table of Contents
Published: 2026/02/06 21:10:25
Recent updates to the labeling of fluorouracil and capecitabine, commonly used chemotherapy drugs, highlight an increased risk of severe, early-onset toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. These changes are crucial for healthcare providers to understand and implement to protect patient safety.
Understanding DPD Deficiency
Dihydropyrimidine dehydrogenase (DPD) is an enzyme responsible for breaking down fluorouracil and capecitabine in the body. A deficiency in this enzyme, which can be genetic or acquired, substantially reduces the body’s ability to metabolize these drugs. This leads to a rapid buildup of the medication, resulting in potentially life-threatening toxicities.
Symptoms of Early-Onset Toxicity
Patients with DPD deficiency who receive fluorouracil or capecitabine may experience severe and early-onset toxicities, including:
- severe Neutropenia: A dangerously low white blood cell count, increasing the risk of infection.
- Severe Mucositis: Inflammation and ulceration of the mucous membranes, causing significant pain and difficulty eating.
- diarrhea: Severe and persistent diarrhea leading to dehydration and electrolyte imbalances.
- Hand-Foot syndrome: Painful redness, swelling, and blistering on the palms of the hands and soles of the feet.
- Neurotoxicity: Neurological symptoms such as confusion, ataxia, and seizures.
these adverse events can occur very quickly after the initiation of treatment, sometimes within the first few days.
Who is at risk?
While DPD deficiency is relatively rare, it’s vital to identify patients who may be at increased risk. Risk factors include:
- Genetic Variations: Certain genetic mutations can lead to reduced DPD activity.
- Prior Chemotherapy Exposure: Previous treatment with 5-fluorouracil can sometimes reduce DPD levels.
- Certain Medical Conditions: Conditions affecting liver function may also impact DPD activity.
Recommendations for Patient Screening and Management
The updated labeling emphasizes the importance of DPD deficiency screening before initiating treatment with fluorouracil or capecitabine. several screening methods are available:
- Genotyping: Testing for specific genetic variations associated with DPD deficiency.
- Phenotyping: Measuring DPD enzyme activity in a sample.
For patients identified as having DPD deficiency, dosage adjustments or choice treatment options should be considered. Close monitoring for signs of toxicity is crucial in all patients, but especially those with known or suspected DPD deficiency.
Impact of Labeling Updates
These labeling updates from regulatory bodies are a direct response to reported cases of severe toxicity and fatalities in patients with undiagnosed DPD deficiency.The goal is to raise awareness among healthcare professionals and ensure that appropriate screening and management strategies are implemented.
Key Takeaways
- Fluorouracil and capecitabine carry a risk of severe toxicity in patients with DPD deficiency.
- Early-onset toxicity can be life-threatening.
- DPD deficiency screening is recommended before initiating treatment.
- Dosage adjustments or alternative treatments should be considered for patients with DPD deficiency.
- Close monitoring for toxicity is essential for all patients.
Frequently Asked Questions (FAQ)
- What is DPD?
- Dihydropyrimidine dehydrogenase is an enzyme that breaks down fluorouracil and capecitabine in the body. A deficiency in this enzyme can lead to toxic drug buildup.
- How common is DPD deficiency?
- DPD deficiency is relatively rare, but prevalence varies depending on ethnicity and population. It’s estimated to affect approximately 3-8% of the population.
- What screening tests are available for
Keep reading